Medicare Enrolled
Dr. Michael Tahery, M.D.
Optician · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Tahery from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tahery?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tahery
Dr. Michael Tahery is an optician specialist in Los Angeles, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Tahery performed 94,998 Medicare services across 3,111 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tahery received a total of $344 from 5 pharmaceutical and/or device companies across 5 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tahery is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in CA
$344 industry payments
Medicare Practice Summary
Medicare Utilization ↗94,998
Medicare services
Top 1% in CA for optician
3,111
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,750 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 18,000 | $17 | $40 |
| Romosozumab injection (Evenity) for osteoporosis | 14,910 | $8 | $18 |
| Inclisiran injection (Leqvio) for cholesterol | 12,212 | $9 | $28 |
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
9,000 | $17 | $41 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 7,720 | $37 | $84 |
| Tezepelumab injection, 1 mg An injection of tezepelumab-ekko, a medication administered in 1 mg doses. |
6,610 | $14 | $38 |
| Ocrelizumab infusion (Ocrevus) for MS | 6,600 | $47 | $115 |
| Injection, mepolizumab, 1 mg | 6,100 | $23 | $57 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
3,650 | $34 | $116 |
| Injection, tildrakizumab, 1 mg | 1,800 | $108 | $271 |
| Omalizumab injection (Xolair) for asthma/allergy | 1,770 | $30 | $75 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
1,685 | $27 | $95 |
| Injection, benralizumab, 1 mg | 810 | $131 | $340 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
689 | $12 | $32 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
381 | $76 | $175 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
310 | $58 | $167 |
| Transvaginal pelvic ultrasound An ultrasound exam using a probe inserted into the vagina to image the uterus, ovaries, fallopian tubes, cervix, and surrounding pelvic structures. |
293 | $106 | $800 |
| Antibody screening test A laboratory test used to detect the presence of specific antibodies in the blood. This screening helps identify immune responses to various conditions or exposures. |
272 | $11 | $200 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
268 | $2 | $25 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
207 | $18 | $50 |
| Bacterial culture and colony count A laboratory test that grows bacteria from a sample to identify the type present and measure the quantity of bacterial growth. |
191 | $10 | $100 |
| Bacterial culture, aerobic A laboratory test that grows and identifies bacteria capable of surviving in oxygen. The results help determine the presence of specific aerobic microorganisms. |
153 | $8 | $200 |
| Limited ultrasound of pelvis A focused ultrasound exam of the pelvic area to evaluate specific structures. This procedure provides images of the pelvis to assist in medical assessment. |
134 | $41 | $400 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
107 | $14 | $38 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
103 | $134 | $352 |
| Fungal culture test A laboratory test that grows and identifies mold or yeast from a sample to detect a fungal infection. |
102 | $8 | $100 |
| Mycoplasma culture A laboratory test that grows and identifies Mycoplasma bacteria from a patient sample to detect infection. |
102 | $15 | $200 |
| Bacterial culture, non-urine, non-blood, non-stool A laboratory test to identify bacteria from a sample other than urine, blood, or stool. The sample is grown in a lab to detect aerobic bacteria. |
101 | $8 | $200 |
| Screening test for pathogenic organisms A laboratory test used to screen for the presence of disease-causing organisms in the body. |
100 | $6 | $100 |
| Urine culture, bacterial identification A laboratory test that grows and identifies bacteria from a urine sample to detect infections. |
99 | $8 | $150 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
68 | $99 | $247 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
65 | $25 | $70 |
| Urine culture, bacterial colony count A laboratory test that measures the number of bacteria growing in a urine sample to help identify infections. |
56 | $8 | $150 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
47 | $120 | $330 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
44 | $164 | $2,400 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
36 | $1 | $1 |
| Endometrial biopsy or polyp removal A procedure to collect a tissue sample from the uterine lining or remove a polyp using a thin, lighted tube inserted through the cervix. |
33 | $1,249 | $5,000 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
31 | $5 | $11 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
28 | $26 | $72 |
| Complex urodynamic pressure measurement A test that measures the pressure of urine flow in the bladder along with urethral and voiding pressures. |
25 | $352 | $1,375 |
| Electronic assessment of bladder emptying A test that uses electronic monitoring to evaluate how well the bladder empties urine. |
25 | $6 | $200 |
| Non-needle muscle activity measurement of bladder and bowel openings This procedure measures and records the electrical activity of muscles at the bladder and bowel openings without using needles. |
25 | $28 | $300 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
22 | $140 | $500 |
| Urethral dilation using endoscope A procedure to widen the urethra using a thin, lighted tube called an endoscope. This helps to open a narrowed urethral passage. |
14 | $294 | $1,200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.7% high complexity
75.1% medium
2.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$344
Total received (2019-2024)
Avg $69/year across 5 years
Bottom 36% in CA for optician
5
Companies
5
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$344 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$25
2023
$152
2022
$22
2020
$22
2019
$122
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Eisai Inc.
$25
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2019-2024) ›
Boston Scientific Corporation
$152
Amgen Inc.
$122
Eisai Inc.
$25
Biogen, Inc.
$22
Channel Medsystems, Inc.
$22
Top 3 companies account for 87.0% of all-time payments
Associated products mentioned in payments ›
EVENITY · Leqembi · Solyx SIS System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Opticians within 10 mi
1,524
Per 100K population
15.5
County median income
$87,760
Nearest hospital
VA GREATER LOS ANGELES HEALTHCARE SYSTEM
1.1 mi
1.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Tahery is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Tahery experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Tahery performed 18,000 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tahery receive payments from pharmaceutical companies?
Yes. Dr. Tahery received a total of $344 from 5 companies across 5 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tahery's costs compare to other opticians in Los Angeles?
Dr. Tahery's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tahery) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Los Angeles
Browse opticians in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Opticians in CA
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in CA
Which CA opticians receive the most from drug and device companies.
By company
Boston Scientific Corporation Payments to Doctors
See all physicians who received payments from Boston Scientific Corporation.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Eisai Inc. Payments to Doctors
See all physicians who received payments from Eisai Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology